Vital Therapies, which is developing bio-artificial liver cells for treatment of acute liver failure, postponed its IPO on Thursday citing poor market conditions. The San Diego, CA-based company was founded in 2003 and had been seeking to raise $75 million by offering 4.4 million shares at $16 to $18 per share. Vital Therapies initially filed confidentially on July 22, 2013. Credit Suisse and William Blair were set to be the joint bookrunners on the deal.
